Biological E gets nod for Phase III trial of its COVID-19 vaccine candidate

Its candidate includes an antigen developed by the Texas Childrens Hospital Center for Vaccine Development and in- licensed from BCM Ventures, Baylor College of Medicines integrated commercialization team, along with Dynavax Technologies Corporations advanced adjuvant CpG 1018TM.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/32Jbxuj
via IFTTT